INVION LIMITED — Capital/Financing Update 2013

Oct 27, 2013

ASX / MEDIA ANNOUNCEMENT

==> picture [161 x 76] intentionally omitted <==

28 October 2013

INVION ENTERS INTO GLOBAL LICENCE AGREEMENT FOR INHALED ZAFIRLUKAST

• Invion announces it has licenced intellectual property to develop inhaled zafirlukast, to be known as INV104

• Zafirlukast is currently marketed by AstraZeneca as Accolate, an oral leukotriene receptor antagonist for the treatment of asthma

• INV104 to be developed as inhaled, non-steroidal, anti-inflammatory treatment for asthma

• Invion EVP R&D and CMO Dr Mitchell Glass led development of oral Accolate to FDA approval

Clinical-stage drug development company Invion Limited (ASX:IVX) today announced the execution of a licence agreement with Accolade Pharma LLC for intellectual property to develop inhaled formulations of zafirlukast for the treatment of asthma and other respiratory conditions.

The agreement provides Invion with an exclusive, worldwide licence to develop and commercialise all inhaled formulations and applications of zafirlukast . A licence fee of $500,000 is payable by Invion to Accolade Pharma LLC over a 12 month period commencing January 2014.

Zafirlukast is a leukotriene receptor antagonist (LTRA) or anti-leukotriene that blocks the action of the cysteinyl leukotriene receptors to reduce inflammation, constriction of the airways, and the build-up of mucus in the lungs.

The oral formulation of zafirlukast , currently marketed as a generic drug as well as by AstraZeneca as Accolate, has recently become available in the public domain due to the expiry of its original patents. Accolade Pharma LLC has created a patent strategy and strategic opportunities to develop non-oral formulations of the drug, aimed at reducing side effects and increasing effectiveness.

Invion aims to develop INV104 for novel inhaled indications using the FDA’s abbreviated 505(b)(2) regulatory pathway.

Invion’s CEO, Dr Greg Collier said, “Invion is delighted to announce this licence agreement. The introduction of zafirlukast into our portfolio as INV104 complements Invion’s existing pipeline of inflammatory and respiratory disease treatments. INV104 represents a potential new inhaled, non-steroidal, anti-inflammatory treatment for asthma, which, similar to INV102 uses a drug with an existing safety profile.”

“The development of INV104 will utilise existing knowledge, skills and competencies in the Invion clinical team, while strengthening Invion’s development pipeline and asset commercialisation opportunities.

“Having been used in over four million people, there is a large safety database for this drug, and as we know, there continues to be a large unmet need for more effective and accessible asthma therapies. Having the INV102 (nadolol) and INV104 (zafirlukast) inhaled programs running in parallel means we can leverage IP and strategic efficiencies to the benefit of the Invion portfolio,” he said.

==> picture [43 x 24] intentionally omitted <==

Dr Mitchell Glass, Invion’s Executive Vice President of R&D and Chief Medical Officer, led the development and submission of Accolate for Zeneca (now AstraZeneca) to its FDA approval letter in 1998, and is a substantial shareholder of Accolade Pharma LLC.

Invion Limited ABN 76 094 730 417

GPO Box 1557, Brisbane, QLD, 4001. P +61 7 3295 0500 F +61 7 3295 0599 www.inviongroup.com

ASX / MEDIA ANNOUNCEMENT

==> picture [161 x 76] intentionally omitted <==

Key terms of the licence

Licensee		Invion Limited
Licensor		Accolade Pharma LLC, a Delaware USA private company (which is a related’
		party of Inv	on by virtue of Dr	itchell	lass relations	hip with the Licens	or).
Term		Until the las	t to expire of the Int	ellectu	al Property Righ	ts in the Licensed	IP.
Licensed	IP	All informaticonnection	on including data,with zafirlukast, ow	contacned or	ts, contracts acontrolled byA	nd other arrangem ccoladePharma	entsLLC.	in
Fees		The total Fepayments, fthe event tthe 12 mon	e is AUD$500,000. Tor a period of 12 mhat the Licensee hath period, then the	he Feeonths, cs net caLicense	will be paid byommencing osh in excess ofe may acceler
Royalties		20% of the Net Sales received by the Licensee in connection with thedevelopment and commercialisation of zafirlukast. Net Sales include thegross amount invoiced by or on behalf of Invion less customary deductions.

FOR MORE INFORMATION CONTACT

Managing Director and CEO: Dr Greg Collier. P: 07 3295 0506 investor@inviongroup.com Media/ IR: Jane Lowe, Buchan Consulting P: 02 9237 2800 jlowe@buchanwe.com.au

About INV104 (zafirlukast)

INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) or anti leukotriene that works by blocking the action of leukotrienes, which are chemicals released by the body as part of the inflammation response. In the lungs, leukotrienes cause the muscles lining the airways to contract, thereby making the airways narrower. They also cause inflammation of the lining of the airways, which results in increased mucus production and further narrowing of the airway. By blocking the actions of leukotrienes, zafirlukast prevents the increased mucus production, inflammation and narrowing of the airways that occurs in asthma - this helps prevent asthma attacks from occurring. Zafirlukast is currently used as a regular oral treatment to prevent asthma attacks, rather than to treat them. The oral version of this drug is a first-in-class anti-leukotriene, which has shown in seven clinical trials an attractive safety and efficacy profile when delivered by inhalation at <1% of the oral dose. Invion is developing an inhaled version of the drug.

About Invion Limited

Invion is a life sciences company focussed on the development of treatments for major opportunities in respiratory disease and autoimmune disease. The Group has three drug assets in development, and three phase II clinical trials, regulated by the Food & Drug Administration (FDA), currently underway in the United States. INV102 (nadolol) a beta blocker ( beta adrenergic inverse agonist ) currently used to treat high blood pressure and migraine, is being repurposed to treat chronic inflammatory airway diseases, including asthma and chronic obstructive pulmonary disease (COPD). INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) or anti-leukotriene that reduces inflammation, constriction of the airways, and the build-up of mucus in the lungs. INV103 (ala-Cpn10) is a modified, naturally occurring human protein shown to reduce interlukin-6 (IL-6), a marker of autoimmune inflammation and a key marker in the chronic inflammatory disease, lupus. Invion is an ASX listed company (ASX:IVX), with its clinical headquarters in Delaware, USA.

==> picture [43 x 24] intentionally omitted <==

Invion Limited ABN 76 094 730 417

GPO Box 1557, Brisbane, QLD, 4001. P +61 7 3295 0500 F +61 7 3295 0599 www.inviongroup.com